Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

被引：27
作者：
Wang, Cenzhu [1 ]
Xu, Kun [1 ]
Wang, Runtian [1 ]
Han, Xin [2 ]
Tang, Jinhai [3 ]
Guan, Xiaoxiang [1 ]
机构：
[1] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Sch Med & Holist Integrat Med, Nanjing 210023, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2021年 / 40卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Breast cancer; Metastatic organotropism; Breast cancer stem cell; Heterogeneity; Seed and soil; CELL MARKERS CD44; STEM-LIKE CELLS; SELF-RENEWAL; PROMOTES; ALDH1; EXPRESSION; CD24; TRANSITION; PLASTICITY; PHENOTYPE;
D O I：
10.1186/s13046-021-02164-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and bone. Breast cancer stem cells (BCSCs) are a small population of breast cancer cells with tumor-initiating ability, which participate in regulating distant metastasis in breast cancer. We investigated the heterogeneity of BCSCs according to biomarker status, epithelial or mesenchymal status and other factors. Based on the classical "seed and soil" theory, we explored the effect of BCSCs on the metastatic organotropism in breast cancer at both "seed" and "soil" levels, with BCSCs as the "seed" and BCSCs-related microenvironment as the "soil". We also summarized current clinical trials, which assessed the safety and efficacy of BCSCs-related therapies. Understanding the role of BCSCs heterogeneity for regulating metastatic organotropism in breast cancer would provide a new insight for the diagnosis and treatment of advanced metastatic breast cancer.
引用
收藏
页数：14
相关论文
共 83 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors [J].
Azaro, Analia ;
Massard, Christophe ;
Tap, William D. ;
Cassier, Philippe A. ;
Merchan, Jaime ;
Italiano, Antoine ;
Anderson, Bailey ;
Yuen, Eunice ;
Yu, Danni ;
Oakley, Gerard, III ;
Benhadji, Karim A. ;
Pant, Shubham .
INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) :1089-1098
[3]   Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling [J].
Brandolini, Laura ;
Cristiano, Loredana ;
Fidoamore, Alessia ;
De Pizzol, Maria ;
Di Giacomo, Erica ;
Florio, Tiziana Marilena ;
Confalone, Giuseppina ;
Galante, Angelo ;
Cinque, Benedetta ;
Benedetti, Elisabetta ;
Ruffini, Pier Adelchi ;
Cifone, Maria Grazia ;
Giordano, Antonio ;
Alecci, Marcello ;
Allegretti, Marcello ;
Cimini, Annamaria .
ONCOTARGET, 2015, 6 (41) :43375-43394
[4]   The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation [J].
Buijs, J. T. ;
van der Horst, G. ;
van den Hoogen, C. ;
Cheung, H. ;
de Rooij, B. ;
Kroon, J. ;
Petersen, M. ;
van Overveld, P. G. M. ;
Pelger, R. C. M. ;
van der Pluijm, G. .
ONCOGENE, 2012, 31 (17) :2164-2174
[5]   Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling [J].
Colacino, Justin A. ;
Azizi, Ebrahim ;
Brooks, Michael D. ;
Harouaka, Ramdane ;
Fouladdel, Shamileh ;
McDermott, Sean P. ;
Lee, Michael ;
Hill, David ;
Madden, Julie ;
Boerner, Julie ;
Cote, Michele L. ;
Sartor, Maureen A. ;
Rozek, Laura S. ;
Wicha, Max S. .
STEM CELL REPORTS, 2018, 10 (05) :1596-1609
[6]   AECHL-1 targets breast cancer progression via inhibition of metastasis, prevention of EMT and suppression of Cancer Stem Cell characteristics [J].
Dasgupta, Aparajita ;
Sawant, Mithila A. ;
Kavishwar, Gayatri ;
Lavhale, Manish ;
Sitasawad, Sandhya .
SCIENTIFIC REPORTS, 2016, 6
[7]   Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types [J].
de Beca, Francisco Ferro ;
Caetano, Pedro ;
Gerhard, Rene ;
Alvarenga, Cesar Augusto ;
Gomes, Madalena ;
Paredes, Joana ;
Schmitt, Fernando .
JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (03) :187-191
[8]   Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer [J].
Di, Lei ;
Liu, Li-Juan ;
Yan, Yong-Ming ;
Fu, Rong ;
Li, Yi ;
Xu, Ying ;
Cheng, Yong-Xian ;
Wu, Zhao-Qiu .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38
[9]   Breast cancer stem cells: Features, key drivers and treatment options [J].
Dittmer, Juergen .
SEMINARS IN CANCER BIOLOGY, 2018, 53 :59-74
[10]   Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis [J].
Doheny, Daniel ;
Sirkisoon, Sherona ;
Carpenter, Richard L. ;
Aguayo, Noah Reeve ;
Regua, Angelina T. ;
Anguelov, Marlyn ;
Manore, Sara G. ;
Arrigo, Austin ;
Jalboush, Sara Abu ;
Wong, Grace L. ;
Yu, Yang ;
Wagner, Calvin J. ;
Chan, Michael ;
Ruiz, Jimmy ;
Thomas, Alexandra ;
Strowd, Roy ;
Lin, Jiayuh ;
Lo, Hui-Wen .
ONCOGENE, 2020, 39 (42) :6589-6605
123456789